Discover
BJDX
Bluejay Diagnostics, Inc.
1.20
2 x 0.92
2 x 1.45
bid
ask
+
0.00
0.00%
2 @ 06:16 AM
1.14 -0.06 (5.00%)
| Ytd | -55.06% | |
| 1y | -81.93% |
1.13
day range
1.32
1.05
52 week range
16.68
| Open | 1.15 | Prev Close | 1.20 | Low | 1.13 | High | 1.32 | Mkt Cap | 1.24M |
| Vol | 372.44K | Avg Vol | 1.39M | EPS | -3.74 | P/E | N/A | Forward P/E | -11.88 |
| Beta | 0.73 | Short Ratio | 0.09 | Inst. Own | 0.95% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 2.73 | 200-d Avg | 4.03 | 1yr Est | 256.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-07 | 2024-09 | 0 | -8 | N/A | N/A |
| 2024-08-14 | 2024-06 | 0 | -256 | N/A | N/A |
| 2024-05-15 | 2024-03 | 0 | N/A | N/A | N/A |
| 2024-03-28 | 2023-12 | -272 | -712 | -440 | -161.76% |
| 2023-11-09 | 2023-09 | -328 | -832 | -504 | -153.66% |
| 2023-08-14 | 2023-06 | -600 | -1100 | -500 | -83.33% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2023-08-03 | Dawson James | Downgrade | Buy | Neutral |
Profile
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers Symphony platform, a technology platform comprising Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. It also provides ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 test for the monitoring of disease progression in critical care settings. Further, it develops cardiac biomarkers, such as hsTNT and NT pro-BNP, as well as other tests using the Symphony platform. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-01-31 | CHASE DONALD R | Director | 792.85K | Stock Award(Grant) |
| 2023-12-12 | DEY INDRANIL | Chief Executive Officer | 233.09K | Purchase |
| 2023-12-12 | DEY SVETLANA | Director | 206.07K | Purchase |
| 2023-01-31 | FISHER KENNETH R | Chief Financial Officer | 113.18K | Stock Award(Grant) |
| 2023-01-31 | GEMIGNANI GARY G | Director | 27.50K | Stock Award(Grant) |
| 2023-01-31 | WURTH DOUGLAS CLARK | Director | 2.31M | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Anson Funds Management LP | 6.39K | 24.27K | 1.16% |
| 2024-09-29 | Sabby Management, LLC | 6.10K | 23.20K | 1.10% |
| 2024-09-29 | Renaissance Technologies, LLC | 2.74K | 10.41K | 0.50% |
| 2024-06-29 | CVI Holdings, LLC | 1.32K | 5.03K | 0.24% |
| 2024-09-29 | UBS Group AG | 1.23K | 4.67K | 0.22% |
| 2024-09-29 | Two Sigma Securities, LLC | 1.05K | 4.00K | 0.19% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity Extended Market Index Fund | 403.00 | 1.53K | 0.07% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 1.00 | 3.00 | 0.00% |
Split
| Split | Date |
|---|---|
| 1 : 4 | 2026-01-29 |
| 1 : 50 | 2024-11-18 |
| 1 : 8 | 2024-06-20 |
| 1 : 20 | 2023-07-24 |